Image source: Vertex Pharmaceuticals.
What: So far, 2016 has been pretty rough on investors in Vertex Pharmaceuticals (NASDAQ: VRTX). Shares of the cystic fibrosis (CF) leader have fallen drastically in the first half of the year, down more than 29% according to data from S&P Global Market Intelligence.